Cilmi-baadheyaasha ka yimid Norway waxay baaritaan ku sameeyeen saamaynta qadar ee khatarta wadnaha
Cilmi-baadhis ayaa muujisay in cudurka hypothyroidism-ka ee sarreeya - heerarka tayroodhka hooseeya - iyo hyperthyroidism - heerarka qanjidhada sare - waxay ku xiran tahay khatarta sii kordheysa ee cudurada wadnaha (CHD). CHD waxay dhacdaa marka jirku uu ku faafo gudaha wadnaha xididdada halbowlayaasha ah, taas oo laga yaabo inuu ka lumo wadnahaaga dhiigga qotodheer. Daraasad lagu sameeyay Norway ayaa cilmi-baadhistan ka qaaday hal tallaabo oo dheeraad ah oo eegay saamaynta caadiga ah ee qanjidhada caadiga ah ee ku jirta khatarta cudurka wadnaha.
Baaritaanka Qatar iyo CHD Khatarta
In ka badan 25,000 qof ayaa lagu daray daraasadda. Ka qaybgalayaasha daraasaddan waxaa loo kala qaybiyey shan qaybood oo kala duwan iyadoo loo eegayo heerka hoormoonka kor u kaca ee hormoonka (TSH):
- TSH: in ka yar 0.50
- TSH: 0.50 ilaa 1.4
- TSH: 1.5 ilaa 2.4
- TSH 2.5 ilaa 3.5
- TSH: 3.6 iyo ka sare
Ujeedada daraasaddan, qiyaasta tixraaca ee LA ayaa lagu qeexay 0.50 illaa 3.5 mIU / L. (Fiiro gaar ah: Qeybaha tixraaca ee shaybaarada ee Maraykanka ayaa badanaa ka ballaaran waxayna ka socdaan qiyaastii 0.50 illaa 5.5mIU / L Tan iyo 2002, qaar ka mid ah dhakhaatiirta indhaha ayaa waxay ku taliyeen in heerkulku hoos u dhaco tiro kala duwan oo ah 0.30 ilaa 3.0.) Caadi ahaan, TSH ee hoos .50 wuxuu muujinayaa hyperthyroidism. Wax kasta oo ka sarreeya 5.5 (jadwalka caadiga ah) waa calaamad muujinaysa ama hypothyroidism.
Inta lagu guda jiro in ka badan siddeed sano oo la socoshada daraasaddan, 228 haween (1.3 boqolkiiba) iyo 182 rag (2.3 boqolkiiba) ayaa ku dhintay cudurka cudurka wadnaha. Kuwaas waxaa ka mid ah, 192 haween iyo 164 rag ah oo heerarka tixraaca ku jira ee kala duwan ee cilmi-baadhayaasha loo adeegsaday daraasaddan.
Qiyaasta 0.50 illaa 1.4 ayaa loo isticmaalay sidii loo xakameyn lahaa kooxaha asaasiga ah, iyo heerarka TSH-ga wuxuu u kordhay boqolleyda ka sarreeya 1.4, "heerka halista", taas oo kiiskan lagu qiyaasay khatarta dhimashada cudurka wadnaha wadnaha, sidoo kale wuxuu ku koray haweenka . (Inkastoo ay jireen qaar ka mid ah kicinta ragga, ma ahan mid ku filan in loo tixgeliyo mid muhiim ah.)
Falanqaynta ayaa lagu soo celiyay labo sano ka dib oo soo noqnoqday, natiijooyinkana waxa ay mar labaad la socdaan baaritaanka hore.
Ugu dambeyntii, cilmi baarayaashu waxay soo gabagabeeyeen in ay jirto xiriir cad oo udhexeeya xiriirka hooseeya ee jirka - hooseeya - qanjirka caadiga ah ee dumarka iyo cudurada wadnaha ee dhimirka.
Cilmi-baadhayaashu waxay sheegeen, in aqoontooda, ma jirin baadhitaano caafimaad oo lagu ogaanayo haddii bedelka hoormoonka tayroodhku uu ka caawin karo ka hortagga cudurka wadnaha wadnaha. Waxay ogaadeen, in cilmi-baaris kale ay muujisay in daweynta beddelidda hormoonnada hormoonnada ee hormoonnada ah ay kor u qaadi karto heerarka kolestaroolka, hagaajineysa hawlaha dareen-celinta (qiyaasta cudurka vascular disease) oo yareynaya calaamadaha kale ee atherosclerosis.
Maxay Tan Taas U Joogtaa Dadweynaha?
Dhab ahaan, natiijooyinkani waxay si gaar ah muhiim ugu yihiin in daraasado dheeraad ah oo la jinsi ah la sameeyo, iyada oo ujeeddo ah in lagu ogaado haddii bedelka hoormoonka tayrood ee dadka Qaaxada ee ka sarreeya 1.4 ka yareeyo khatarta cudurka halbowlayaasha wadnaha.
Daraasado dheeraad ah ayaa muhiimad weyn u leh haweenku waxay u badan tahay inay ku dhacaan cudurka tayroodh iyo cudurka wadnaha waa sababta ugu weyn ee dhimashada haweenka.
Marka la eego in aanu horey u ogeyn in beddelidda hormoonka tayroodhku uu hagaajin karo calaamadaha kala duwan ee cudurada wadnaha, waxaa jira caddayn sii kordhaya oo ah in beesha quutul daroogada iyo shaybaarrada ay ubaahan tahay inay ugu dambeyntii gaarto heshiis ka mid ah qaadashada qiyaasta tixraaca darajada.
Hoos-u-qaadidda tixraaca tixraaca waxay ka caawin kartaa dadka inay helaan daaweynta tayroodhka ah halkii ugu fiicnayd.
Xigasho:
Åsvold, Bjørn MD; et. al. "Heerotropin Heerarka iyo Khatarta Cudurka Wadnaha Cisbitaalka ee Dhiigga: Daraasadda HUNT," Arch Intern Intern. 2008; 168 (8): 855-860.